NK Cells, Chemokines and Chemokine Receptors
Authors:
J. Kopecký 1; O. Kopecký 2,3
Authors place of work:
Klinika onkologie a radioterapie, FN Hradec Králové
1; II. interní klinika, FN Hradec Králové
2; Oddělení klinické onkologie, Oblastní nemocnice Náchod, a. s.
3
Published in the journal:
Klin Onkol 2010; 23(1): 5-9
Category:
Reviews
Summary
NK cells are an important component of natural immunity, which provides a defence response against viruses, bacterial and parasitic intracellular pathogens and tumour cells. NK cells are capable of rapid responses without prior sensitization and cytotoxic response is independent of the presence of the antigens of the major histocompatibility system. NK cells produce a number of cytokines (e. g. INF‑ γ, GM‑CSF and TNF‑β) and chemokines and in this way they regulate both the natural and acquired immune response. By contrast, NK cells are regulated both positively and negatively by cytokines and chemokines produced by other immune cells. Attention is focused on the possibility of influencing the tumour process by using cytokine‑ and chemokine‑activated NK cells. In studies in mice models as well as in several clinical trials, it has been shown that the presence of cytotoxic cells in tumour stroma is associated with a more favourable prognosis of cancer. There is also plenty of evidence that in tumour stroma a number of cytokines and chemokines are produced which may have ambivalent effects.
Key words:
natural killer cells – chemokines – chemokine receptors – cytokines
Zdroje
1. French AR, Yokoyama WM. Natural killer cells and viral infections. Curr Opin Immunol 2003; 15: 45–51.
2. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293–299.
3. Gregoire C, Chasson L, Luci C et al. The trafficking of natural killer cells. Immunol Rev 2007; 220: 169–182.
4. Ferlazzo G, Thomas D, Lin SL et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig like receptors and become cytolytic. J Immunol 2004; 172: 1455–1462.
5. Biron CA, Nguyen KB, Pien GC et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189–220.
6. Taub DD. Natural killer cell chemokine interactions. Biologic effects on natural killer cell trafficking and cytolysis. In: Rollins BJ. Chemokines and cancer. Totowa: Humana Press Inc. 1999: 73–93.
7. Jass JR. Lymphocitic infiltration and survival in rectal cancer. J Clin Pathol 1986; 39: 585–589.
8. Zhang L, Conejo Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203–213.
9. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538–18543.
10. Coca S, Perez Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997; 79: 2320–2328.
11. Hsia JY, Chen JT, Chen CY et al. Prognostic significance of intratumoral natural killer cells in primary resected esophageal squamous cell carcinoma. Chang Gung Med J 2005; 28: 335–340.
12. Villegas FR, Coca S, Villarrubia VG et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002; 35: 23–28.
13. Beano A, Signorino E, Evangelista A et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patiens. J Translat Med 2008; 6: 25.
14. Yan L, Anderson GM, DeWitte M et al. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42: 793–802.
15. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438.
16. Lanier LL, Le AM, Civin CI et al. The relationship of CD16 (Leu 11) and Leu 19 (NKH 1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480–4486.
17. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol 2001; 22: 633–640.
18. Cooper MA, Fehniger TA, Turner SC. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 2001; 97: 3146–3151.
19. André P, Spertini O, Guia S et al. Modification of P selectin glykoprotein ligandy 1 with natural killer cell restricted sulfated lactosamine creates n alternace ligandy for L selectin. Proc Natl Acad Sci USA 2000; 97: 3400–3405.
20. Jacobs R, Hintzen G, Kemper A et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31: 3121–3126.
21. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell derived IL 2: a potential new link between adaptive and innate immunity. Blood 2003; 101: 3052–3057.
22. Rollins BJ. Chemokines. Blood 1990; 90: 909–928.
23. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217–242.
24. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891–928.
25. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Imunity 2000; 12: 121–127.
26. Bacon K, Baggiolini M, Broxmeyer H et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002; 22: 1067–1068.
27. Muchy PM, Baggiolini M, Charo IF et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145–176.
28. Constantin G, Majeed M, Giagulli C et al. Chemokines trigger immediate β2 integrin affinity and mobility changes: differential regulation and roles in lymfocyte arrest under flow. Imunity 2000; 13: 759–769.
29. van Deventer HW, Serody JS, McKinnon et al. Transfection of macrophage inflammatory protein 1α into B16, F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors. J Immunol 2002; 169: 1634–1639.
30. Vicari AP, Ait Yahia S, Chemin K et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165: 1992–2000.
31. Gao JQ, Tsuda Y, Katayama K et al. Antitumor effect by interleukin 11 receptor α locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res 2003; 63: 4420–4425.
32. Guo J, Chen T, Wang B et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol Lett 2003; 89: 1–7.
33. Xin H, Kikuchi T, Andarini S et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol 2005; 35: 1371–1380.
34. Ueno T, Toi M, Saji H et al. Significance of macrophage chemoattractant protein 1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282.
35. Lavergne E, Combadiere B, Bonduelle O et al. Fractalkine mediates natural killer dependent antitumor responses in vivo. Cancer Res 2003; 63: 7468.
36. Lavergne E, Combadiere C, Iga M et al. Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration. J Immunol 2004; 173: 3755–3762.
37. Campbell JJ, Qin S, Unutmaz D et al. Unique subpopulations of CD56+NK and NK T peripheral blood lymphocytes identified by chemokine receptor expression. J. Immunol 2001; 166: 6477–6482.
38. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001; 97: 367–375.
39. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540–550.
40. Maghazachi AA. Intracellular Signalling Pathways Induced by Chemokines in Natural Killer Cells. Cell Signal 1999; 11: 385–390.
41. Ji TH, Grossmann M, Ji I. G Protein coupled Receptors., J Biol Chem 1998; 273: 17299–17302.
42. Maghazachi AA. Insights into seven and single transmembrane spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol Rev 2005; 57: 339–357.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2010 Číslo 1
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Very Small Breast Cancer, HER2 Positive, and Trastuzumab in Adjuvant Treatment
- NK Cells, Chemokines and Chemokine Receptors
- Demonstration of the Effect of Estrogen and Progesterone Receptors on Survival in Breast Cancer without Cytostatic and Hormonal Treatment in a Small Set of Patients
- Long‑term Response of Liver Metastases of Breast Cancer to Capecitabine – Case Report